People wear their face masks waiting in line for an emergency food distribution at the 88th Street Temple Church of God in Christ on April 14, 2020 in Los Angeles, California, during the coronavirus pandemic.Frederic J. Brown | AFP | Getty ImagesThe Covid-19 outbreak in Los Angeles County is likely far more widespread than previously thought, up…
A new study conducted by the University of Southern California along with the LA County Department of Public Health indicates the presence of antibodies for COVID-19 in between 2.8 and 5.6% of the population of LA County, suggesting that between 221,000 and 442,000 individuals had the infection — up to 55 times more people than…
A law firm in Scottsdale, Arizona, tested employees who hoped, with the prick of a finger, to learn if they might be immune. In Laredo, Texas, community leaders secured 20,000 of the new tests to gauge how many residents had been infected. In Chicago, a hospital screened firefighters to help determine whether they could safely…
Covid-19 diagnostic tests from scaling up adequately.As President Trump presses to reopen the country and several states are considering lifting lockdowns in the next few weeks, widespread screening is considered critical. On Friday, Mr. Trump cheered the F.D.A.’s emergency approval of some antibody tests, saying they would support efforts to get Americans back to work…
Published: October 30, 2026, 10:16 pm Several reports of children choking have led to an FDA warning against Once Upon A Time snacks. The warning covers all flavors, quantities, lots and dates of Once Upon A Farm Tractor Wheels Organic, Toddler Soft-Baked Bars. The FDA has received several reports that describe infants ages 1.5 to
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.